# Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes

> **NCT00104962** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Childhood Myelodysplastic Syndromes
- de Novo Myelodysplastic Syndromes
- Previously Treated Myelodysplastic Syndromes
- Refractory Anemia
- Refractory Anemia With Excess Blasts
- Refractory Anemia With Ringed Sideroblasts
- Refractory Cytopenia With Multilineage Dysplasia
- Secondary Myelodysplastic Syndromes
- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00104962
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2014-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00104962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00104962, "Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00104962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*